Zosano Pharma (ZSAN) Getting Somewhat Favorable News Coverage, Study Shows

Headlines about Zosano Pharma (NASDAQ:ZSAN) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zosano Pharma earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.4927349617371 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the media stories that may have impacted Accern’s scoring:

Separately, ValuEngine upgraded Zosano Pharma from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st.

Shares of Zosano Pharma (ZSAN) traded down $0.03 on Tuesday, hitting $0.54. The stock had a trading volume of 370,500 shares, compared to its average volume of 441,160. The firm has a market cap of $21.11 and a price-to-earnings ratio of -0.46. Zosano Pharma has a one year low of $0.50 and a one year high of $3.54.

Zosano Pharma (NASDAQ:ZSAN) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). research analysts anticipate that Zosano Pharma will post -0.9 earnings per share for the current fiscal year.

In related news, Director Kenneth Greathouse acquired 95,000 shares of Zosano Pharma stock in a transaction that occurred on Friday, December 1st. The stock was acquired at an average price of $0.62 per share, for a total transaction of $58,900.00. Following the transaction, the director now directly owns 95,000 shares of the company’s stock, valued at approximately $58,900. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have purchased a total of 200,000 shares of company stock valued at $123,450 in the last 90 days. Insiders own 2.83% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zosano Pharma (ZSAN) Getting Somewhat Favorable News Coverage, Study Shows” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/09/zosano-pharma-zsan-getting-somewhat-favorable-news-coverage-study-shows.html.

Zosano Pharma Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Insider Buying and Selling by Quarter for Zosano Pharma (NASDAQ:ZSAN)

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply